These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21351746)

  • 1. Aminothiazolomorphinans with mixed κ and μ opioid activity.
    Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
    J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
    Provencher BA; Sromek AW; Li W; Russell S; Chartoff E; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2013 Nov; 56(21):8872-8. PubMed ID: 24107104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
    Zhang A; Xiong W; Hilbert JE; DeVita EK; Bidlack JM; Neumeyer JL
    J Med Chem; 2004 Apr; 47(8):1886-8. PubMed ID: 15055988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
    Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
    J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
    Zhang B; Zhang T; Sromek AW; Scrimale T; Bidlack JM; Neumeyer JL
    Bioorg Med Chem; 2011 May; 19(9):2808-16. PubMed ID: 21482470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
    Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-affinity carbamate analogues of morphinan at opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1508-11. PubMed ID: 17276685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
    Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
    Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
    J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.
    Cheng K; Kim IJ; Lee MJ; Adah SA; Raymond TJ; Bilsky EJ; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Rothman RB; Jacobson AE; Rice KC
    Org Biomol Chem; 2007 Apr; 5(8):1177-1190. PubMed ID: 17406716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
    Neumeyer JL; Peng X; Knapp BI; Bidlack JM; Lazarus LH; Salvadori S; Trapella C; Balboni G
    J Med Chem; 2006 Sep; 49(18):5640-3. PubMed ID: 16942040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
    Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
    J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans.
    Cheng K; Lee YS; Rothman RB; Dersch CM; Bittman RW; Jacobson AE; Rice KC
    J Med Chem; 2011 Feb; 54(4):957-69. PubMed ID: 21247164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.